Biogen (BIIB) PT Lowered to $272 at Cantor Fitzgerald
Tweet
Share
E-mail
Get Alerts BIIB Hot Sheet
Price: $199.71 --0%
Rating Summary:
26 Buy, 17 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 4 | Down: 11 | New: 23
Rating Summary:
26 Buy, 17 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 4 | Down: 11 | New: 23
Join SI Premium – FREE
Cantor Fitzgerald lowered its price target on Biogen (NASDAQ: BIIB) to $272.00 (from $289.00) while maintaining a Neutral rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Novel Patented Myelin Drug-Discovery Strategy Targets Massive Unmet Need in Multiple Sclerosis
- International Regulatory Pathways Have Supported Drug Development Across Biotech and Pharma
- Ralliant Corp. (RAL) PT Raised to $85 at Morgan Stanley: 'organic pathway to sustained HSD into 2027'
Create E-mail Alert Related Categories
Analyst PT ChangeRelated Entities
Cantor FitzgeraldSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
